RADIATION-INDUCED OSTEOGENIC-SARCOMA OF C3H MOUSE - EFFECTS OF CORYNEBACTERIUM-PARVUM AND WBI ON ITS NATURAL-HISTORY AND RESPONSE TO IRRADIATION

被引:31
作者
CHOI, CH [1 ]
SEDLACEK, RS [1 ]
SUIT, HD [1 ]
机构
[1] MASSACHUSETTS GEN HOSP,BOSTON,MA 02114
关键词
D O I
10.1016/0014-2964(79)90078-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
An osteogenic sarcoma, which appeared at 316 days following single dose 5000 rad to the leg of C3H mouse, has been studied as early generation F2 and F3 transplants in syngenic hosts with respect to local growth, pattern of spread, and response to local irradiation in normal, C. parvum treated, and whole body irradiated hosts. Mean survival of untreated mice was 126 days after transplantation. Grossly evident metastatic tumor appeared in 85% of these mice; in 47 of 48 animals metastases were seen in the lung. Corynebacterium parvum given intravenously as a single dose of 350 μg at 96 hr after tumor transplant retarded tumor growth: regression was observed in 10 of 19 tumors, 3 of 19 mice were cured of their osteosarcomas and mean survival was prolonged from 126 to 173 days, in one study where i.v. C. parvum was given when tumor was 5 mm, 1 of 13 mice was cured by C. parvum alone. Although 5000 rad resulted in 100% of tumor destruction in normal mice; 49% died of metastatic tumor to the lung. In C. parvum treatment mice only 16% died of metastatic tumor. The radiation doses which achieved control of half of the irradiated 8 mm diameter tumors were 4350 and 3600 rad for normal and C. parvum treated hosts, respectively. While body irradiation 600 rad given 24 hr prior to tumor transplant had an opposite effect to Corynebacterium parvum. © 1979.
引用
收藏
页码:433 / 442
页数:10
相关论文
共 20 条
[1]  
FRIEDLAENDER GE, 1975, CANCER-AM CANCER SOC, V36, P1631, DOI 10.1002/1097-0142(197511)36:5<1631::AID-CNCR2820360516>3.0.CO
[2]  
2-W
[3]  
FRIEDMAN B, 1973, BONE CERTAIN ASPECTS, P339
[4]   CESIUM-137 IRRADIATOR FOR SMALL LABORATORY-ANIMALS [J].
HRANITZKY, EB ;
ALMOND, PR ;
SUIT, HD ;
MOORE, EB .
RADIOLOGY, 1973, 107 (03) :641-644
[5]  
ISRAEL L, 1975, IMMUNOLOGICAL ASPECT, P485
[6]   ROLE OF HIGH-DOSE METHOTREXATE WITH CITROVORUM FACTOR RESCUE IN TREATMENT OF OSTEOGENIC-SARCOMA [J].
JAFFE, N ;
TRAGGIS, D ;
CASSADY, JR ;
FILLER, RM ;
WATTS, H ;
FREI, E .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1977, 2 (3-4) :261-266
[7]  
JENKINS RDT, 1977, MANAGEMENT PRIMARY B, P163
[8]  
MERKER PC, 1976, P AM ASSOC CANC RES, V17, P78
[9]  
MILLER DR, 1975, P AM ASSOC CANC RES, V16, P66
[10]  
MOORE M, 1973, BONE CERTAIN ASPECTS, P411